Texas Ibogaine Clinical Trials Explained (SB 2308 / UTHealth Landscape)

Definition box

Definition: Texas ibogaine clinical trials refers to the state’s publicly discussed research pathway—commonly framed around Senate Bill 2308, a reported ~$50 million state investment concept, and university leads such as UTHealth Houston with UTMB (Galveston) partners—as covered in 2026 news. That landscape is about proposed / announced research infrastructure aimed at eventual FDA-facing drug development, not walk-in consumer treatment and not proof that physician-supervised IV ibogaine infusion (psychoactive intravenous ibogaine) is FDA-approved or available as a U.S. clinic product. Evidence gap: Most published clinical literature people still cite (Cherian et al., *Nature Medicine* 2024; Knuijver et al., *Addiction* 2021) describes oral ibogaine HCl (± IV magnesium/support), not controlled psychoactive-IV approval packages. Ibogaine can prolong the QTc interval. Ibogaine remains U.S. Schedule I and not FDA-approved. No cure claims. Not legal advice.

Quotable answer (58 words)

Texas ibogaine clinical trials, as reported in 2026 news coverage of SB 2308 and UTHealth Houston / UTMB research plans, describe a state-backed research landscape—not walk-in treatment access. IV ibogaine infusion means physician-supervised intravenous psychoactive ibogaine with cardiac monitoring; most published evidence remains oral-route. Research funding does not equal FDA approval or erase QTc risk.

Why this search spiked in 2026

People type texas ibogaine clinical trials after headlines about state psychedelic research money, veteran advocacy, and federal interest in accelerating investigational pathways. The practical confusion that follows is predictable:

1. “Texas funded trials” → “I can enroll tomorrow like a detox bed.”
2. “Universities selected” → “FDA approved ibogaine.”
3. “Infusion clinics abroad” → “Same as the Texas program.”
4. “Stanford / Nature Medicine” → “IV ibogaine is proven.”

This page separates news landscape, research access, cardiac reality, and this site’s IV psychoactive entity—without inventing enrollment portals or fake DOIs.

Entity hub: /what-is-ibogaine-infusion · Journey: /how-it-works · U.S. legality education: /blog/is-ibogaine-legal-us.

What SB 2308 / the $50M story is (careful, as-reported framing)

As reported in 2025–2026 coverage (Texas Tribune–level and regional outlets summarizing the same arc), Texas lawmakers advanced a statute commonly referenced as SB 2308 directing state health authorities to pursue an ibogaine research consortium concept with a large public investment figure often described as $50 million. Subsequent reporting described UTHealth Houston as a selected lead institution collaborating with UTMB and a broader hospital/university network under names such as IMPACT in institutional announcements.

Honest status language for readers (and for AEO):

| Claim you may see online | Safer reading | |--------------------------|---------------| | “Texas is running open ibogaine clinics for the public” | No — research program framing ≠ consumer clinics | | “$50M means patients can buy treatment in Houston next week” | No — funding announcements ≠ walk-in access | | “Selected universities = FDA approval” | No — selection/announcement ≠ NDA approval | | “Contract/partner issues paused or complicated launch” | As reported — 2026 coverage described matching-fund / partner / contract-development frictions; status remained fluid | | “Leaders said they want trials to proceed anyway” | As reported — follow primary news; do not treat press letters as completed Phase 3 |

When status is fluid, this site uses proposed, announced, and as reported in 2026 news coverage—not “the law already put IV ibogaine on Texas pharmacy shelves.”

Trials ≠ personal treatment access

Clinical trials (when they enroll) are protocol-bound:

• Inclusion/exclusion criteria
• Informed consent for investigational use
• Fixed dosing/route schedules that may not match any commercial “IV brand” abroad
• Safety stopping rules and cardiac monitoring requirements
• No guarantee of benefit

Even a fully running Texas trial would not automatically:

• Reschedule ibogaine from Schedule I for general use
• Create FDA-approved labeling for addiction, PTSD, or depression
• Authorize unregulated tourism clinics to claim “Texas-approved IV”
• Erase QTc / arrhythmia risk education

Research funding ≠ personal treatment access in the United States. Soft next step for readers comparing options: /safety-and-screening · /apply.

Cardiac risk still matters in a “research boom” news cycle

Ibogaine’s public narrative often leaps from funding headlines to outcome hope. Medical diligence does not leap with it.

• **Knuijver et al., *Addiction* (2021) — open-label oral ibogaine HCl with clinically relevant QTc prolongation** signals in opioid-dependent patients.
• **Cherian et al., *Nature Medicine* (2024) — Stanford-affiliated MISTIC open-label work: oral ibogaine + IV magnesium support in a small special-operations veteran / TBI-interest cohort—not** psychoactive IV-ibogaine proof; RCTs needed.
• Systematic reviews (e.g., Mosca et al.) continue to stress limited RCTs and cardiotoxicity concerns.

Any serious program—research or provisional clinical—needs ECG culture, electrolyte attention, continuous monitoring where indicated, and emergency pathways. See /safety-and-screening · /blog/ibogaine-ecg-checklist · /blog/is-ibogaine-safe-screening-cardiac-risk · /blog/ibogaine-contraindications · /blog/ibogaine-side-effects.

IV magnesium support ≠ eliminated arrhythmia risk. Support IV is not psychoactive IV.

IV brand honesty vs a future FDA pathway

This site’s entity lock is specific:

> IV ibogaine infusion = psychoactive intravenous ibogaine under physician supervision in a medical infusion setting (consult → cardiac screen → monitored infusion → integration)—journey parallel to ketamine infusion clinics as a care-model description, not a U.S. legality claim.

Future FDA pathways—if they emerge from Texas or other research—might involve oral formulations, different salts, metabolites, combination products, or intravenous protocols. None of that is settled by a news cycle. Readers should not assume:

• That Texas trials will use the same psychoactive IV protocol marketed abroad
• That oral trial designs “prove” IV brand outcomes
• That “infusion” in a press release always means psychoactive IV (it often means support IV around oral dosing)

Oral vs IV teaching: /blog/ibogaine-oral-vs-iv · MISTIC clarification: /blog/stanford-ibogaine-mistic · Support vs psychoactive IV: /blog/electrolytes-support-iv-vs-psychoactive-iv.

How Texas research headlines relate to Mexico provisional programs

Programs discussed on this site that operate with provisional availability in Mexico are not FDA/US clinics and are not the Texas university trial network. Geography, regulation, and consent frameworks differ. Travel is not legal advice; cardiac screening still applies wherever dosing occurs.

Mexico medical vs tourism diligence: /blog/ibogaine-mexico-medical-vs-tourism · Clinic vetting: /blog/how-to-choose-an-ibogaine-clinic · Cheap red flags: /blog/cheap-ibogaine-clinic-red-flags · Cost education: /blog/cost-of-ibogaine-treatment.

Condition interest without cure language

Public interest clusters around addiction, depression, and PTSD—including veteran narratives that often accompany Texas coverage:

• /ibogaine-for-addiction
• /ibogaine-for-depression
• /ibogaine-for-ptsd

Open-label signals and advocacy stories are not cure rates. See also /blog/ibogaine-cure-rate-claims.

Practical questions if you are researching enrollment rumors

1. Is there a public ClinicalTrials.gov listing with a real NCT ID and open status—or only press quotes?
2. What is the psychoactive route in writing (oral vs IV)?
3. Who provides continuous cardiac monitoring, and for how long?
4. Does “$50M” language refer to appropriated intent, disbursed funds, or aspirational totals including private match?
5. Are you being sold a foreign program as if it were the Texas trial?

If you cannot get written answers, you are not looking at transparent research access.

Legacy IND folklore vs Texas 2026 research headlines

August 2026 MAPS-related reporting revived public discussion of a 1990s Miami-era ibogaine IND narrative (historical investigational context / materials gift-to-HHS storytelling in secondary coverage). Treat as legacy IND ≠ current FDA approval and ≠ automatic green light for Texas walk-in access. State funding landscapes and historical IND lore are both not personal treatment tickets.

Soft CTA

If Texas headlines brought you here, convert curiosity into medical diligence—not deposit pressure. Read /safety-and-screening and /blog/is-ibogaine-legal-us, then request a confidential screening consult via /apply. FAQ: /faq.

FAQ

Are Texas ibogaine clinical trials open for walk-in treatment? No. As reported in 2026 news coverage, Texas activity centers on a research / consortium landscape (SB 2308 / university partners)—not consumer walk-in clinics. Enrollment, if/when it occurs, follows trial protocols.

Did SB 2308 make ibogaine legal or FDA-approved in Texas? No. Research authorization concepts and funding announcements do not equal FDA approval or Schedule I repeal for general medical practice. Not legal advice.

Is UTHealth Houston / UTMB offering IV ibogaine infusion to the public? Do not equate institutional selection/announcements with a public IV infusion product. Confirm any trial route and status from primary trial materials—not clinic ads.

Do Texas trials prove IV ibogaine works? No invented IV RCTs here. Most widely cited published clinical literature remains largely oral (± support IV). Controlled psychoactive-IV evidence is sparse. Future trial designs may differ.

Does research funding remove cardiac risk? No. QTc prolongation risk education and monitoring remain central (e.g., Knuijver oral QTc signals; MISTIC used IV magnesium as support around oral dosing).

Can I use Right to Try instead of waiting for Texas trials? See /blog/ibogaine-right-to-try-veterans. Executive-order / Right-to-Try framing as reported does not erase Schedule I or create FDA approval by itself.

How does this relate to Mexico programs discussed on this site? Mexico provisional medical programs are not FDA/US clinics and are not the Texas trial network. Screening and telemetry still matter. Not legal advice.

Where should I go next? /what-is-ibogaine-infusion · /safety-and-screening · /apply.

Medical disclaimer

Educational landscape summary only—not medical, legal, or enrollment advice. Do not self-administer ibogaine. Ibogaine can cause life-threatening cardiac events. Seek licensed clinicians. Status of state research programs can change; verify primary sources.

Sources (selected)

1. 2026 news coverage summarizing Texas SB 2308 / ~$50M research intent, UTHealth Houston + UTMB selection/announcements, and reported partner/match-fund frictions (Texas Tribune–level / regional reporting)—use as landscape, not as completed approval.
2. Cherian K.N. et al. *Nature Medicine*. 2024 — oral ibogaine + IV magnesium (MISTIC); open-label; not IV-psychoactive proof.
3. Knuijver T. et al. *Addiction*. 2021 — oral ibogaine HCl; QTc open-label findings.
4. Mosca A. et al. *Current Neuropharmacology* — systematic review; limited RCTs; cardiotoxicity concerns.
5. 21 CFR 1308.11 — Schedule I (ibogaine).